Gene Therapy for Rare Disorders Europe Summit
October 22 - 24, 2018 - London UKHanson Wade
info@hansonwade.com
Phone:+4402031418700
Dedicated to Realizing the Commercial Potential of Gene TherapiesNow is a crucial time for the gene therapy field, as the ripple effects of the pioneering first US gene therapy approval are being felt globally, setting new benchmarks and posing unexpected questions.Rather than early stage basic science, the Gene Therapy for Rare Disorders Europe Conference is solely devoted to addressing the latest clinical, manufacturing, regulatory and commercialization challenges facing this rapidly evolving field. This is a comprehensive guide to define your commercial path forward.Here’s a snapshot of the companies who attended last year:Pfizer – Shire – Lysogene – BioMarin – Novasep – Horama – Orchard Therapeutics – Avrobio – Genzyme – Astellas – uniQure – Syneos Health – REGENXBIO – Chiesi – TIGET – Syncona – GenSight – GSK – Covance – Bioverativ – Cell Therapy Catapult – Vertex – DAK Gesundheit – MHRA – Vivet – Oxford Genetics – Innovate UK – Gilead – IQVIA – Servier – Rocket PharmaJoin your colleagues and accelerate the progress of the next generation of gene therapies that show improved efficacy, enhanced safety and commercial viability.Early booking and group discounts are available. Register early to ensure the best possible rate for you and your colleagues.